En poursuivant votre navigation, vous acceptez l'utilisation de cookies destinés à des fins de mesure d'audience, à améliorer la performance de ce site et à vous proposer des services et contenus personnalisés. En savoir plus


Sensome launches the first connected device for stroke treatment

Sensome, a start-up that completed a journey through École Polytechnique and the X-Up Acceleration program, has announced another financing round of €4.6 million for the launch of its first connected medical device for treating stroke.

The technology start-up Sensome is getting ready for a revolution in connected medical equipment thanks to the creation of the world’s smallest sensor with the ability to identify biological tissue. On June 11, 2018, the company announced that it would be receiving a second round of funding. The company received a sum of €4.6 million for the launch of its first product: Clotild, the intelligent neurovascular guide. Kurma Partners led a consortium of venture capitalists (Paris-Saclay Seed Fund and Idinvest) and historical investors, joined by the BNP Paribas Développement fund.

Sensome’s technology combines impedance microsensors with algorithms based on artificial intelligence, in order to identify biological tissues instantly and with unparalleled accuracy. The sensors are so thin that they can be inserted into any medical device.

Clotild, the first product to incorporate this technology, is an electronic guide for the treatment of cerebrovascular accidents (strokes), the prime cause of disability worldwide. A stroke occurs when a blood clot blocks an artery in the brain and causes millions of nerve cells to die every minute. Depending on the nature of the clot, it can take hours for an emergency procedure to unblock the artery. This product will enable instant identification of the clot’s composition, which will help doctors select the most appropriate tools according to each patient, in order to restore blood flow as quickly as possible and reduce aftereffects.

"This round of financing will enable us to carry out a clinical trial and launch Clotild on the European market, while also allowing us to explore new applications of our technology," states Franz Bozsak, President and Co-founder of Sensome.